Outcomes and characteristics of nonmelanoma skin cancers in patients with myeloproliferative neoplasms on ruxolitinib
Rampotas, A. Carter-Brzezinski, Luke Somervaille, Tim C P Forryan, J. Panitsas, F. Harrison, C. Witherall, R. Innes, A. J. Wallis, L. Butt, N. M.
Rampotas, A.
Carter-Brzezinski, Luke
Somervaille, Tim C P
Forryan, J.
Panitsas, F.
Harrison, C.
Witherall, R.
Innes, A. J.
Wallis, L.
Butt, N. M.
Citations
Altmetric:
Abstract
Nonmelanoma skin cancers (NMSCs) in ruxolitinib-treated patients with myeloproliferative neoplasms behave aggressively, with adverse features and high recurrence. In our cohort, mortality from metastatic NMSC exceeded that from myelofibrosis. Vigilant skin assessment, counseling on NMSC risks, and prospective ruxolitinib-NMSC studies are crucial.
Authors
Rampotas, A.
Carter-Brzezinski, Luke
Somervaille, Tim C P
Forryan, J.
Panitsas, F.
Harrison, C.
Witherall, R.
Innes, A. J.
Wallis, L.
Butt, N. M.
Psaila, B.
Mead, A. J.
Carter, M.
Godfrey, A. L.
Laing, H.
Garg, M.
Francis, S.
Ewing, J.
Teh, C. H.
Cowen, H. B.
Dyer, P.
McConville, C.
Wadelin, F.
Sahra, A.
McGregor, A.
Kulakov, E.
McLornan, D. P.
Lambert, J.
Carter-Brzezinski, Luke
Somervaille, Tim C P
Forryan, J.
Panitsas, F.
Harrison, C.
Witherall, R.
Innes, A. J.
Wallis, L.
Butt, N. M.
Psaila, B.
Mead, A. J.
Carter, M.
Godfrey, A. L.
Laing, H.
Garg, M.
Francis, S.
Ewing, J.
Teh, C. H.
Cowen, H. B.
Dyer, P.
McConville, C.
Wadelin, F.
Sahra, A.
McGregor, A.
Kulakov, E.
McLornan, D. P.
Lambert, J.
Description
Date
2024
Publisher
Collections
Keywords
Type
Correspondence
Citation
Rampotas A, Carter-Brzezinski L, Somervaille TCP, Forryan J, Panitsas F, Harrison C, et al. Outcomes and characteristics of nonmelanoma skin cancers in patients with myeloproliferative neoplasms on ruxolitinib. Blood. 2024 Jan 11;143(2):178-82. PubMed PMID: 37963262.